NASDAQ:NKNantkwest Stock Price, Forecast & News

Nantkwest's stock was trading at $3.52 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NK shares have increased by 164.5% and is now trading at $9.31.
View which stocks have been most impacted by COVID-19.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nantkwest in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Nantkwest.

Nantkwest is scheduled to release its next quarterly earnings announcement on Tuesday, August 18th 2020.
View our earnings forecast for Nantkwest.

Nantkwest Inc (NASDAQ:NK) announced its earnings results on Monday, May, 11th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.02. The biotechnology company had revenue of $0.02 million for the quarter. Nantkwest had a negative return on equity of 51.94% and a negative net margin of 112,350.85%.
View Nantkwest's earnings history.

1 brokers have issued twelve-month price objectives for Nantkwest's stock. Their forecasts range from $18.00 to $18.00. On average, they expect Nantkwest's share price to reach $18.00 in the next twelve months. This suggests a possible upside of 93.3% from the stock's current price.
View analysts' price targets for Nantkwest.

News articles about NK stock have trended positive on Friday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Nantkwest earned a daily sentiment score of 2.7 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next few days.
View the latest news about Nantkwest.

Nantkwest saw a increase in short interest in January. As of January 31st, there was short interest totaling 3,750,000 shares, an increase of 29.3% from the January 15th total of 2,900,000 shares. Based on an average trading volume of 1,980,000 shares, the short-interest ratio is presently 1.9 days. Currently, 41.0% of the company's stock are short sold.
View Nantkwest's Short Interest.

Some companies that are related to Nantkwest include Relay Therapeutics (RLAY), Sorrento Therapeutics (SRNE), Momenta Pharmaceuticals (MNTA), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Twist Bioscience (TWST), Immunovant (IMVT), Legend Biotech (PCVX), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Mesoblast (MESO), Sangamo Therapeutics (SGMO), BAVARIAN NORDIC/S (BVNRY), Revolution Medicines (RVMD) and Coherus Biosciences (CHRS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nantkwest investors own include Sorrento Therapeutics (SRNE), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Gilead Sciences (GILD), Opko Health (OPK), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX), Inovio Pharmaceuticals (INO), Matinas BioPharma (MTNB) and VBI Vaccines (VBIV).

(NK) raised $150 million in an IPO on Tuesday, July 28th 2015. The company issued 7,000,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray acted as the underwriters for the IPO and MLV & Co. was co-manager.

Nantkwest trades on the NASDAQ under the ticker symbol "NK."

Nantkwest's stock is owned by a number of institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (0.18%), Meridian Investment Counsel Inc. (0.10%), California Public Employees Retirement System (0.06%), Creative Planning (0.06%), State of Wisconsin Investment Board (0.05%) and Aigen Investment Management LP (0.04%). Company insiders that own Nantkwest stock include Barry J Simon, Frederick W Driscoll, John C Thomas, Patrick Soon-Shiong and Steve Gorlin.
View institutional ownership trends for Nantkwest.

NK stock was purchased by a variety of institutional investors in the last quarter, including Meridian Investment Counsel Inc., Bank of New York Mellon Corp, California Public Employees Retirement System, State of Wisconsin Investment Board, Aigen Investment Management LP, New York State Common Retirement Fund, Principal Financial Group Inc., and American International Group Inc..
View insider buying and selling activity for Nantkwest.

Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NK stock can currently be purchased for approximately $9.31.

Nantkwest has a market capitalization of $1.01 billion and generates $40,000.00 in revenue each year. The biotechnology company earns $-65,790,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Nantkwest employs 161 workers across the globe.

The official website for Nantkwest is www.nantkwest.com.

Nantkwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected]